John C. Chang, MD, PhD, Author at Grand Rounds in Urology

John C. Chang, MD, PhD

Banner MD Anderson Cancer Center

Gilbert, Arizona

Dr. John C. Chang is a radiologist and cancer center physician at the Banner MD Anderson Cancer Center in Gilbert, Arizona. He works in general radiology, focusing on body imaging and innovative business development. He is also a member of the adjunct research faculty at Arizona State University in Tempe, Arizona, where he participates in research related to radiation dosimetry and compressed sensing. Dr. Chang received his MD and a PhD in Electrical Engineering from the University of Illinois at Urbana-Champaign. After receiving an Internal Medicine Internship from the University of Illinois College of Medicine in Chicago, he went on to a Diagnostic Radiation Residency and a Body Imaging Fellowship, both at the Stanford University Medical Center in Stanford, California. Dr. Chang’s research, both independent and through Arizona State University, focuses largely on the application of nanoparticles in cancer therapy and diagnostics, as well as in radiation detection. His other research interests and projects include multiparametric MRI for cancer diagnosis and treatment response assessment, the application of intravoxel incoherent motion components for tumor assessment, and nonspecific quenching of quantum dot with small molecules, as well as methods of specifying quenching.

Disclosures:

Talks by John C. Chang, MD, PhD

Can MR Imaging Help Triage Bladder Cancer Patients?

Posted by John C. Chang, MD, PhD | May 2019

John C. Chang, MD, PhD, examines the potential of MRI for staging bladder cancer, emphasizing MRI’s facility in differentiating between muscle invasive and non-muscle invasive bladder cancer (NMIBC). He also acknowledges that MRI scanning can lead to overstaging, and that CT can be effective for detecting higher stages of bladder cancer.

MR Guided Biopsy

Posted by John C. Chang, MD, PhD | Apr 2019

John C. Chang, MD, PhD, compares advantages and disadvantages of MRI-guided biopsy and transrectal ultrasound-guided (TRUS) biopsy. He emphasizes MRI-guided biopsy’s detection rates and its effectiveness in patients undergoing repeat biopsies, while acknowledging its relative inefficiency and limitations in low grade cancers.